Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price)

In April 2026, 8,200 of the 11th Stock Acquisition Rights were exercised, and 820,000 shares were delivered. The number of unexercised rights at month-end was 11,649.

Worth reading
72In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
820000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status of warrants with exercise price adjustment clauses (monthly report)

Who receives how much

Number of shares delivered during the month: 820,000 shares (820,000 new shares; 0 treasury shares transferred)

Macquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)

The lower thin line represents the existing number of shares to which these shares will be added.

発行済株式総数

9.96% (820,000 shares delivered for all series combined / 8,229,900 listed shares outstanding as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥174, ¥170, ¥176, ¥175, ¥177, ¥180 and ¥181. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 30,000; unexercised as of the end of the preceding month: 19,849; unexercised as of the end of the month under review: 11,649
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing
2 February 2026: Issuance of the 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Clauses) (issue price and total amount: Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status of warrants with exercise price adjustment clauses (monthly report)
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 820,000 shares (820,000 new shares; 0 treasury shares transferred)
Intended allotteeMacquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)
Dilution Rate9.96% (820,000 shares delivered for all series combined / 8,229,900 listed shares outstanding as of the payment date for the issuance)
Total number of issued shares13,175,000 shares (as of the end of the month preceding the month under review) → Not disclosed
Exercise priceExercise prices during the month: ¥174, ¥170, ¥176, ¥175, ¥177, ¥180 and ¥181. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 30,000; unexercised as of the end of the preceding month: 19,849; unexercised as of the end of the month under review: 11,649
Procedures under the Corporate Code of ConductDescribes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing2 February 2026: Issuance of the 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Clauses) (issue price and total amount: Not disclosed)
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 11th Stock Acquisition Rights in April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori